TY - JOUR T1 - Clinical in-hospital mortality profile of pulmonary embolism JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2020.3454 VL - 56 IS - suppl 64 SP - 3454 AU - Loreta Agolli AU - Juliana Gjerazi AU - Silvana Bala AU - Jul Bushati Y1 - 2020/09/07 UR - http://erj.ersjournals.com/content/56/suppl_64/3454.abstract N2 - Introduction: Pulmonary embolism is an important clinical entity with considerable mortality despite advances in diagnosis and treatment.Aims and Objectives: Clinical mortality profile for acute pulmonary embolism (PE) patients.Methods: This is a retrospective study of in- hospital PE mortality during 2017.Results: Out of 177 deaths (4.2% of hospitalizations for pulmonary disease), 18 (10.2% of total deaths or 6.7% of 266 patients hospitalized with PE) were due to PE. The predominant number of deaths (72.2%) was ≥65 years of age (mean 69.94 ± 11.75, range 44 - 88) and males (83.3%). Concomitant diseases: 16(89%) patients, 9 with two or more. Evaluated as specific nosology: cardiovascular disease - 31%, respiratory -28%, neuropsychiatric -13.8%, neoplastic -10.3%. The clinical symptoms: dyspnea at rest 100%, thoracic pain - 66.7%, hemoptysis -27.8%, fever - 22.2%, syncope- 72.2%, shock- 77.8%, cyanosis - 22.2% of patients. Risk factor is identified in 16 (88.9%) patients, two or more risk factors - 8 (44.4%) patients. sPESI resulted in all -high-risk cases. D-Dimer resulted >4000 ng/mL -68.8% cases. Echocardiography resulted normal -59%, ventricular dilatation -18%, increased PSAP -18% cases, and increased PSAP plus ventricular dilatation -6%. Chest radiographs: normal -17.6%, elevated hemi diaphragm -35.3%, atelectasis -11.8%, Palla sign -11.8%, Westermark sign -17.6%, pleural effusion -35.3%, and infiltrate -5.9%. Vasal localization of the thrombi in angioCT: segmental -33.3%, lobar -20%, and primary -46.7%.Conclusions: Mortality from PE is higher than that of respiratory diseases in total; predominantly in older age patients, with concomitant disease, and risk factors.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 3454.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -